Страна: Армения
Язык: английский
Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
xylometazoline (xylometazoline hydrochloride)
GlaxoSmithKline Consumer Healthcare S.A.
R01AA07
xylometazoline (xylometazoline hydrochloride)
1mg/ml
spray nasal with menthol and eucalypt flavour
10ml plastic vial with metering pump
OTC
Registered
2019-11-27
GSK Consumer Healthcare S.A. CH-1260, Nyon, Switzerland Global Regulatory Affairs Global Labelling & Compliance OTRIVIN _ _ 0.1% MOISTURISING FORMULA (F.5) Metered-Dose Spray 0.1% with menthol and eucalypt Xylometazoline hydrochloride 0.1% CORE SUMMARY OF PRODUCT CHARACTERISTICS (SMPC) Amendment date(s): Release date: 07 Aug 2019 Next Update date: Number of pages: 8 Property of GSK Consumer Healthcare S.A. Confidential May not be used, divulged, published or otherwise disclosed without the consent of GSK Consumer Healthcare S.A. CONFIDENTIAL GSK Consumer Healthcare S.A. Core SmPC Page 2 Otrivin 0.1 1. NAME OF THE MEDICINAL PRODUCT .................................................................. 3 2. QUALITATIVE AND QUANTITATIVE COMPOSITION......................................... 3 3. PHARMACEUTICAL FORMS..................................................................................... 3 4. CLINICAL PARTICULARS ......................................................................................... 3 4.1. Therapeutic indications....................................................................................... 3 4.2. Posology and method of administration ............................................................. 3 4.3. Contra-indications .............................................................................................. 4 4.4. Special warnings and special precautions for use .............................................. 4 4.5. Interactions with other medicinal products and other forms of interaction........ 4 4.6. Pregnancy and lactation ...................................................................................... 4 4.7. Effects on ability to drive and use machines ...................................................... 4 4.8. Undesirable effects ............................................................................................. 5 4.9. Overdose ............................................................................................................. 5 5. PHARMACOLOGIC Прочитать полный документ